()
 
 

Overview

Ardea Biosciences of Carlsbad, California is a biotechnology company focused on the discovery and development of small-molecule therapeutics in virology, oncology and inflammation. The Company has two product candidates in clinical development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is also investigating RDEA806 for the treatment of gout. In oncology, the Company is investigating a mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.


Contact Information

1009 Oak Hill Road
Suite 201
Lafayette, CA 94549

tel: 925-906-5331
fax:
http://www.ardeabiosciences.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NASDAQ
Industry: Drug Manufacturers - Other
Market Cap: $187.6M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.